SCHEMBL4067989

SCHEMBL4067989

COC(=O)c1ccc(Cn2ccnc2CN(C)Cc2nccn2CCCN2CCC3(CCN(CC(C)C)CC3)C2)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.40
ALDH1A1 P00352 7/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HSP90AA1 P07900 2/20 0.35
HSP90B1 P14625 2/20 0.35
CYP3A4 P08684 9/20 0.35
CYP2D6 P10635 6/20 0.35
CYP1A2 P05177 2/20 0.35
MAPK1 P28482 2/20 0.34
MEN1 O00255 1/20 0.34
TSHR P16473 4/20 0.33
USP2 O75604 3/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4075344 0.92 CXCR4 (0.42) CXCR4ALDH1A1KMT2ACYP3A4CYP2D6
SCHEMBL4386441 0.89 CXCR4 (0.47) CXCR4ALDH1A1KMT2AL3MBTL1CYP3A4
SCHEMBL4386577 0.85 CXCR4 (0.39) CXCR4KMT2AHSP90AA1HSP90B1CYP3A4
SCHEMBL4394761 0.84 OPRD1 (0.44) CXCR4ALDH1A1HSP90AA1HSP90B1CYP3A4
SCHEMBL4251274 0.83 CXCR4 (0.49) CXCR4ALDH1A1KMT2ACYP3A4CYP2D6
SCHEMBL4067508 0.81 CXCR4 (0.41) CXCR4ALDH1A1CYP3A4CYP2D6CYP1A2
SCHEMBL4532140 0.81 CXCR4 (0.41) CXCR4ALDH1A1CYP3A4CYP2D6CYP1A2
SCHEMBL4065760 0.81 CXCR4 (0.41) CXCR4ALDH1A1CYP3A4CYP2D6CYP1A2
SCHEMBL4069969 0.81 CXCR4 (0.37) CXCR4ALDH1A1CYP3A4CYP2D6CYP1A2
SCHEMBL4073134 0.80 CXCR4 (0.40) CXCR4ALDH1A1CYP3A4CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2055705-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF Ono Pharmaceutical CO., LTD. (JP) 2009-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF CXCR4, CXCL12, CXCR1 CXCR4 1/4885ALDH1A1 297/4885NPSR1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.